GEMSTONE Oncology logo
MenuClose

Therapeutic Options for Recurrent Platinum-Resistant Ovarian Cancer

  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide

Download Slide Module

Platinum resistance is one of the most difficult challenges in treating recurrent ovarian cancer.

Typically characterized by disease progression within 6 months of platinum-based chemotherapy, recurrent platinum-resistant ovarian cancer is associated with poor prognosis. Current treatment goals consist of disease control, prolongation of life, improvement in quality of life, and palliation. Available treatments are limited to options such as chemotherapy ± anti-angiogenics or PARPi monotherapy. However, many new therapies and combination approaches are under investigation.

Explore the module further to learn more about treatment options for recurrent platinum-resistant ovarian cancer—or download the module for later review offline.

Platinum-resistant ovarian cancer remains one of today’s most difficult clinical challenges. Currently available treatments provide only short-term responses, highlighting a significant unmet need.

OLIVER DORIGO, MD, PhD
Stanford University
GEMSTONE Committee Member: Oliver Dorigo, MD, PhD
GEMSTONE Oncology infographic - Platinum resistance is one of the most challenging aspects of ovarian cancer treatment

Download Infographic